Active Implants in Delaware,US, has named Lex Giltaij as the company's new president and chief operating officer.

Prior to joining the company, Giltaij held senior executive positions in Stryker Benelux and Stryker Biotech, where he was responsible for the establishment of the company’s respective businesses in the Benelux and Europe.

He also served at Francis Medical Technologies, where he operated the European subsidiary, and created the international market for the X-STOP interspinous implant.

In the new role, Giltaij will be responsible for completing clinical studies of the Nusurface Meniscus implant, designed for treating pain and disability arising from osteoarthritis (OA) of the knee.

Active Implants board chairman and CEO Henry Klyce said Giltaij’s results-oriented approach and ability to think strategically will play a pivotal role in the future of the company.

"Locating our subsidiary’s headquarters in The Netherlands will help us achieve our strategic vision and allow us to introduce the NUsurface Meniscus Implant into international markets, which is increasingly recognized as a valuable step to help ensure the successful launch of a new medical device in the U.S.," Klyce added.

"The Company’s Clinical & Regulatory functions will remain in Memphis, its U.S. corporate headquarters."